Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bronchopulmonary Disposition of Delafloxacin in Healthy Adults
NCT03534622Phase 1Completed
- Sponsor
- Melinta Therapeutics
- Start
- Apr 2018
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of delafloxacin in community-acquired bacterial pneumonia (CAP), sponsored by Melinta Therapeutics. Primary endpoints: Time to Maximum Plasma Concentration at Day 4, Maximum Plasma Concentration at Day 4 and 4 more. Started Apr 2018; status: completed.
02
Drugs
delafloxacin
03
Conditions
community-acquired bacterial pneumonia (CAP)
Beyond the preview
Go deeper on NCT03534622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03534622.